Detalles de la búsqueda
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256976
2.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
3.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31825569
4.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34860318
5.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
; 124(9): 1581-1591, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33723394
6.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Oncologist
; 26(8): e1327-e1338, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028126
7.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264439
8.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Breast Cancer Res Treat
; 188(2): 449-458, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909203
9.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152285
10.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838010
11.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Future Oncol
; 16(24): 1801-1813, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32633563
12.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402321
13.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat
; 178(1): 121-133, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368034
14.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28238593
15.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28800861
16.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30621698
17.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 30(2): 334-343, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992310
18.
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
J Clin Oncol
; : JCO2301409, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38422473
19.
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Aliment Pharmacol Ther
; 59(7): 865-876, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38327102
20.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38448600